Big Pharma Keeps CNS Pipeline In-House; GI/Metabolism Left To Specialists
This article was originally published in Pharmaceutical Approvals Monthly
For the analysis, published in the September/October 2010 Tufts CSDD Impact Report, researchers tracked clinical activity at the 50 largest pharmaceutical and biopharmaceutical companies ranked by total 2006 worldwide sales. The study analyzed factors related to clinical approval success for compounds entering the clinic between 1993 and 2004.
You may also be interested in...
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011